SNX10: A Potential Drug Target and Biomarker for Various Diseases
SNX10: A Potential Drug Target and Biomarker for Various Diseases
SNX10, also known as sorting nexin 10, is a protein that is expressed in various tissues throughout the body. It is a member of the N-cadherin gene family, which is responsible for cell-cell adhesion and survival signaling. SNX10 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The N-cadherin gene family is composed of four genes: NCDH1, NCDH2, NCDH3, and NCDH4. These genes encode a protein that consists of a transmembrane domain and a cytoplasmic tail. The transmembrane domain is responsible for the protein's ability to interact with extracellular signaling molecules, while the cytoplasmic tail is involved in the protein's stability and localization to the cell surface.
SNX10 is a 14-kDa protein that is expressed in various tissues, including muscle, heart, brain, and pancreas. It is predominantly expressed in the brain, where it is found in the postsynaptic density of neurons. SNX10 is also expressed in other tissues, including the lungs, liver, and kidney.
SNX10 has been shown to play a role in various physiological processes in the brain, including cell migration, neurotransmitter release, and synaptic plasticity. It is involved in the regulation of synaptic strength and the modulation of neurotransmitter release, which are critical for the functioning of neurons and the development of neurodegenerative diseases.
SNX10 has also been shown to be a potential drug target for various diseases. For example, SNX10 has been identified as a potential therapeutic target for Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells. Studies have shown that SNX10 levels are decreased in the brains of individuals with Alzheimer's disease, and that inhibiting the activity of SNX10 has been shown to protect against the neurodegeneration associated with the disease.
SNX10 has also been shown to be a potential biomarker for various diseases, including cancer. For example, SNX10 has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that SNX10 may be a useful biomarker for the early detection and diagnosis of these diseases.
In addition to its potential clinical applications, SNX10 is also of interest to researchers as a potential drug target. Studies have shown that SNX10 is involved in multiple cellular signaling pathways, including the regulation of cell adhesion, neurotransmitter release, and cell survival. This makes it a potential target for small molecules that can modulate these processes. Additionally, the N-cadherin gene family is well-studied, and the identification of SNX10 as a potential drug target has the potential to shed light on the underlying mechanisms of neurodegenerative diseases.
In conclusion, SNX10 is a protein that is expressed in various tissues throughout the body and has been shown to play a role in various physiological processes in the brain. Its potential clinical applications as a drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand the role of SNX10 in various diseases and to develop effective treatments.
Protein Name: Sorting Nexin 10
Functions: Probable phosphoinositide-binding protein involved in protein sorting and membrane trafficking in endosomes. Plays a role in cilium biogenesis through regulation of the transport and the localization of proteins to the cilium. Required for the localization to the cilium of V-ATPase subunit ATP6V1D and ATP6V0D1, and RAB8A. Involved in osteoclast differentiation and therefore bone resorption
The "SNX10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX10 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
SNX10-AS1 | SNX11 | SNX12 | SNX13 | SNX14 | SNX15 | SNX16 | SNX17 | SNX18 | SNX18P23 | SNX18P24 | SNX18P3 | SNX19 | SNX2 | SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21
